Breaking News, Collaborations & Alliances

MorphoSys Hits Milestones

Pfizer, OncoMed advance HuCAL programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG has received milestone payments from two partners in its HuCAL-derived fully human antibody program. Pfizer delivered an undisclosed payment in connection with the IND filing in December 2010 and subsequent initiation of a Phase I trial one such antibody in the therapeutic area of oncology. MorphoSys also received payment from OncoMed when the program for antibody OMP-59R5 reached Phase I in patients with advanced solid tumors. That antibody is part of OncoMed’s Notch pathway ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters